Global Hepatitis C Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado

La hepatitis C es un virus que produce inflamación en el hígado y, si no se trata a tiempo, puede provocar daños graves en el hígado. La sangre infectada de un paciente propaga la hepatitis C. El VIH/SIDA, el consumo excesivo de alcohol, la exposición a toxinas y algunos medicamentos pueden provocar una infección por hepatitis C causada por un virus. La encefalopatía hepática, la aparición de sangrado y hematomas con facilidad, la fatiga, la falta de apetito, la ictericia, la orina de color oscuro, la picazón en la piel, la ascitis y la deglución en las piernas son síntomas de hepatitis. Según un estudio de encuesta publicado por los "Centros para el Control y la Prevención de Enfermedades" en 2016, la hepatitis C afectó a 2,4 millones de personas en los Estados Unidos.

Data Bridge Market Research analiza que el mercado de la hepatitis C se valoró en USD 48,51 mil millones en 2021 y se espera que alcance los USD 134,54 mil millones para 2029, registrando una CAGR del 13,60% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

El virus de la hepatitis C causa la hepatitis C, una infección vírica que afecta principalmente al hígado. La cirrosis es frecuentemente el resultado y puede tener consecuencias como insuficiencia hepática, neoplasias malignas y varices esofágicas y gástricas. Por lo general, no hay síntomas al principio de una infección. Los medicamentos antivirales son un tipo de medicamento que se utiliza para tratar enfermedades víricas como el VIH, el herpes, la hepatitis y la gripe. Las vacunas son la forma más común de administración de estos medicamentos. Además, la mayoría de estos medicamentos se utilizan para tratar infecciones víricas específicas, pero un puñado selecto (tratamientos antivirales de amplio espectro) son eficaces contra diferentes formas del virus. Los medicamentos antivirales que se utilizan para tratar infecciones víricas del hígado, como la hepatitis, se conocen como agentes antivirales hepáticos.

Dinámica del mercado de la hepatitis C

Conductores

• Aumento de la prevalencia de la hepatitis

La creciente prevalencia de la hepatitis es un factor importante que impulsa la tasa de crecimiento del mercado de la hepatitis C. Según los datos de la Organización Mundial de la Salud (OMS) publicados en julio de 2021, se estima que 58 millones de personas padecen una infección crónica por el virus de la hepatitis C y que cada año se producen 1,5 millones de nuevas infecciones. El virus de la hepatitis C es un patógeno que se transmite por la sangre y la forma más común de contraerlo es por contacto con pequeñas cantidades de sangre. Esto ocurre con frecuencia como resultado de inyecciones inadecuadas y de una mala atención sanitaria. 

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la hepatitis C es el creciente gasto en atención médica, que ayuda a mejorar su infraestructura.

Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la información sobre la hepatitis C ampliarán el mercado. Además, los altos ingresos disponibles y el cambio en el estilo de vida de las personas darán lugar a la expansión del mercado de la hepatitis C. Junto con esto, el aumento de la población geriátrica y el aumento del turismo médico mejorarán la tasa de crecimiento del mercado.

Oportunidades

• Aumento del número de actividades de investigación y desarrollo       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hepatitis C market growth. In March 2021, Dicerna Pharmaceuticals and Roche began a Phase II combo trial for the treatment of chronic hepatitis infection with the experimental GalXC RNAi candidate, RG6346. As a result, market research and development activities are crucial to improve market expansion.

• Launch of new products

The launch of new products is estimated to boost the new market opportunities. Mavyret (glecaprevir and pibrentasvir) pills, for instance, were approved by the US Food and Drug Administration in April 2019 to treat six genotypes of hepatitis C virus (HCV) in children aged 12 to 17. Furthermore, in June 2021, Gilead Sciences, Inc. got FDA approval for Epclusa for the treatment of chronic hepatitis C virus (HCV) in children under the age of three, regardless of HCV genotype or severity of liver disease.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hepatitis C market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the treatment will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about hepatitis C will pose major challenges to the market’s growth rate. Additionally, the dearth of skilled professionals and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hepatitis C market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatitis C market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hepatitis C market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global hepatitis C market Scope

The hepatitis C market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Hepatitis C
• Chronic Hepatitis C
• Other

Treatment

• Antiviral Drugs
• Telbivudine
• Entecavir
• Tenofovir disoproxil
• Lamivudine
• Others
• Vaccine
• Immune Modulator Drugs
• Pegylated interferon
• Interferon alpha
• Surgery
• Others

Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Ultrasound
• MRI
• CT scan
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hepatitis C market Regional Analysis/Insights

The hepatitis C market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hepatitis C market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hepatitis C market because of the growing presence of major key players and the rising number of research and development activities will further propel the market’s growth rate in this region. Additionally, an increase in number of FDA approval drugs will further propel the market’s growth rate in this region. 

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and growing government initiatives in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hepatitis C market Share Analysis

The hepatitis C market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatitis C market.

Some of the major players operating in the hepatitis C market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Cadila Pharmaceuticals (India) 
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (U.S.)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)

SKU-53473